Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by CCAbbott888on Apr 26, 2019 10:03am
124 Views
Post# 29674056

RE:Ccabbott Lazard as a licensing deal for ryplasim how much

RE:Ccabbott Lazard as a licensing deal for ryplasim how much
edrose wrote: Is that worth 
re checkpoints for ryplasim stated all the time and hard work re chemistry is done so submitting bla very soon will be more positive news

last year lost 238 million. They took down accounting practice of 150 million re ivig
2019 cut r&d by 30 million
one time plasma sale of around 14 million with offers they did not consider plus atm plus eg salp converts only 100 million not 228 million we have lots of money

re consonance IF THEY DONT PUBLICLY STATES THEY WILL NOT PARTICIPATE IN OFFERING ASK YOURSELF WHY 

edrose I don't know what kind of deal or partnership Prometic will be able to secure via Lazard.

With regards to Consonance, they are a new tute investor of Prometic, it's not a common practice for a third party to issue any NR with regards to their own investment stragegy to Prometic's shareholders.  For me, I don't think that they will take part in the rights, but I understand that many here may hold a different view.

Bullboard Posts